EGFR and non-small cell lung carcinoma: In a retrospective study based on the world health organization (WHO) pharmacovigilance database VigiBase, among 98,765 adverse reactions reported with NSCLC-targeted therapies including EGFR-TKIs, 1,783 (1.8%) were cardiac arrhythmias (126).